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Primary ciliary dyskinesia (PCD) describes a family of rare
genetic disorders affecting ciliary motility in several organ
systems. The respiratory defects that can lead to lung fail-
ure, however, are most concerning. New treatments for
PCD are needed that prevent progressive lung damage and
we aim to develop gene therapy to achieve this. DNAH5 is
the gene most frequently mutated in PCD. It encodes a
large 500kDa structural protein with ATPase activity that
powers ciliary movement. PCD rarity, the shortage of geno-
typed patient samples and lack of suitable animal models
means that better model systems are needed in which to
study gene therapies. A further challenge is that gene trans-
fer of DNAH5 will require an efficient non-viral delivery
vector capable of packaging this gene, which is too large
for commonly used viral vectors. To model PCD we have
used RNA interference to silence DNAH5 in normal
human bronchial epithelial cells grown in air-liquid inter-
face cultures. Cells were transduced with a lentivirus
expressing an shRNA for DNAH5. Silencing of DNAH5
expression was demonstrated and preliminary evidence
that the cilia were immotile. We have cloned DNAH5 from
mRNA of human ciliated cells into a mammalian expres-
sion vector and sequenced it. The DNAH5 clone expressed
both mRNA and protein in transfected cells. Transfections
were performed with a nanocomplex formulation com-
prising liposomes and targeting peptides that we have
developed for DNAH5 gene transfer to the respiratory
epithelium. We are now able to investigate PCD gene ther-
apy using these models, DNAH5 constructs and vector
delivery system.
Author details
1UCL Institute of Child Health,UK. 2University of Leicester, UK.
Published: 16 November 2012
doi:10.1186/2046-2530-1-S1-P109
Cite this article as: Munye et al.: Towards gene therapy for primary
ciliary dyskinesia. Cilia 2012 1(Suppl 1):P109.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: m.munye@ich.ucl.ac.uk
1UCL Institute of Child Health,UK
Full list of author information is available at the end of the article
Munye et al. Cilia 2012, 1(Suppl 1):P109
http://www.ciliajournal.com/content/1/S1/P109
© 2012 Munye et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
